trastuzumab deruxtecan + durvalumab

This drug is a **combination therapy** consisting of **trastuzumab deruxtecan**, an antibody-drug conjugate (ADC), and **durvalumab**, an immune checkpoint inhibitor. - **Trastuzumab deruxtecan** targets and binds to HER2-expressing tumor cells using a humanized anti-HER2 monoclonal antibody. Once bound, the ADC is internalized, and its cytotoxic payload (a topoisomerase I inhibitor—deruxtecan) is released inside the tumor cell through cleavage of a linker by lysosomal cathepsins, causing inhibition of DNA replication and apoptosis. - **Durvalumab** is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and CD80 and restoring antitumor immune responses by T cells. This combination aims to both **target and kill HER2-expressing cancer cells directly** and **enhance immune-mediated tumor cell destruction**. It is being investigated primarily for **stage III HER2-expressing inflammatory breast cancer** in neoadjuvant settings[1][5][7].

Brand names

ImfinziEnhertu

Other names

fam-trastuzumab deruxtecan-nxkitrastuzumab deruxtecandurvalumab